Antibody Drug Conjugates Market, By Product Type (Adcetris, Kadcyla, Enhertu, Trodelvy, Padcev, Others), By Linker Type (Non-cleavable Linker, Cleavable Linker), By Application (Blood Cancer, Breast Cancer, Ovary Cancer, Lung Cancer, Skin Cancer, Brain Tumor, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-commerce), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Sep 2023

Code : CMI181

Pages :210

Formats :

Excel and PDF

Industry : Pharmaceutical

Market News

Global Antibody Drug Conjugates Market: Key Developments

On August 7, 2023, Duality Biologics (Suzhou) Co. Ltd., a clinical-stage biotech company, announced that it had expanded its collaboration with BioNTech SE, a biotechnology company, to develop, manufacture, and commercialize DB-1305, a third ADC candidate, globally, excluding Mainland China, Hong Kong Special Administrative Region, and Macau Special Administrative Region. DB-1305 is currently in a Phase 1/2 clinical trial for solid tumors (NCT05438329). The agreement expands on the strategic partnership announced by the companies in April 2023.

On May 16, 2023, Sony Corporation, a Japan-based multinational conglomerate corporation, and Astellas Pharma Inc., a pharmaceutical company, announced a collaborative research agreement to develop a novel Antibody-drug Conjugate (ADC) platform in oncology based on Sony's proprietary polymeric material, "KIRAVIA Backbone."

On May 12, 2023, LaNova Medicines Ltd, a clinical-stage innovative drug research and development company, announced an exclusive license agreement for LM-305, a pre-clinical stage Antibody Drug Conjugate (ADC) targeting G protein-coupled receptor, class C, group 5, member D (GPRC5D), with AstraZeneca. AstraZeneca will be granted an exclusive global license to research, develop, and commercialize LM-305 under the terms of the licensing agreement.

On May 7, 2023, Bliss Biopharmaceutical (Hangzhou) Co., Ltd., a clinical-stage biopharmaceutical company developing differentiated Antibody-drug Conjugate (ADC) therapeutics, announced a clinical trial collaboration agreement with an option for strategic collaboration with Eisai Co., Ltd., a Japan-based multinational pharmaceutical company, for BB-1701, an eribulin-payload-based ADC directed against Human Epidermal Growth Factor 2 (HER2).

In June, 2022, ProfoundBio, a biotech company focused on the development of novel targeted therapies, announced the completion of a US$70 million Series A+ financing round led by Sequoia China. In the last two years, ProfoundBio has raised more than US$ 138 million. ProfoundBio will use the proceeds to advance PRO1184 and PRO1160 into Phase 1 clinical trials. PRO1184 is a folate receptor alpha (FR)-directed ADC with the potential to treat multiple solid tumors, while PRO1160 is a CD70-directed ADC with indications in both hematological and solid tumors.

Global Antibody Drug Conjugates Market: Key Trends

Funds raised by startups for development of potential ADC candidates: ADC have gained significant traction in recent years, and more players are entering the market; however, some lack financial capital to develop their robust pipeline of ADC. This has encouraged startups to raise funds through financing round; such initiatives are anticipated to support the development of the ADC market over the projected period. For instance, on April 13, 2023, Novo Holdings A/S, a leading international life sciences investor, announced a new investment in Alentis Therapeutics AG, a clinical-stage biotechnology company, of US$ 105 million in Series C financing. The company is developing breakthrough treatments for organ fibrosis and Claudin-1 (CLDN1)-positive tumors. The funding will be used to support the clinical development of Alentis' lead investigational products, ALE.F02 and ALE.C04, as well as the development of the CLDN1 platform. CLDN1 antibody drug conjugates (ADC) and bi-specific antibodies are being engineered using the platform.